Empreses emergents
2014
PEPTOMYC SLNova generació de pèptids penetrants cel·lulars (CPP) dirigits a l'oncoproteïna Myc per al tractament del càncer
Adreça
Carrer de Natzaret 115, 08035 Barcelona, Espanya
Dades financeres
Propietat CERCA
Barcelona, Spain
2006
Vall d’Hebron Institut d’Oncologia (VHIO)
Contacte del Centre CERCA
MD
Mario De la Cuesta Rivero
Vall d’Hebron Institut d’Oncologia (VHIO)Altres accionistes públics catalans
Logotip
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.
Descripció del producte
Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market.
the Omomyc peptide itself displays excellent cell penetrating properties and can efficiently enter cells and exert a strong anti-Myc activity that results in arrest/death of cancer cells. Peptomyc now is developing the Omomyc mini-protein – and improved variants – into clinically viable therapeutics for the treatment of cancer patients.
the Omomyc peptide itself displays excellent cell penetrating properties and can efficiently enter cells and exert a strong anti-Myc activity that results in arrest/death of cancer cells. Peptomyc now is developing the Omomyc mini-protein – and improved variants – into clinically viable therapeutics for the treatment of cancer patients.